aspirin has been researched along with Depressive Disorder, Major in 15 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 7.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 3.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "The USPSTF recommends aspirin for the prevention of stroke and heart attack for those at risk, and screening for major depression and childhood obesity." | 3.76 | USPSTF recommendations you may have missed amid the breast cancer controversy. ( Campos-Outcalt, D, 2010) |
| "Aspirin was inferior to placebo on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) at week 12." | 2.94 | Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin. ( Amminger, GP; Baird, S; Berk, M; Brodie, RE; Chanen, AM; Cotton, SM; Davey, CG; Dean, OM; Dodd, S; Ferguson, NO; Giorlando, F; Harrigan, SM; Hetrick, S; Incerti, L; Kerr, M; Mackinnon, A; Mazza, C; McGorry, P; Mohebbi, M; Mullen, E; Phelan, M; Quinn, AL; Ratheesh, A; Rice, S; Schäfer, MR; Weller, A, 2020) |
| "In a two-year study, forty people with major depressive disorder were randomly assigned to groups that received an SSRI (escitalopram) or an SNRI (duloxetine), each group received concomitant ASA (100 mg) or a placebo." | 2.84 | Selective Serotonergic (SSRI) Versus Noradrenergic (SNRI) Reuptake Inhibitors with and without Acetylsalicylic Acid in Major Depressive Disorder. ( Dubois, T; Jacques, D; Lepiece, B; Reynaert, C; Zdanowicz, N, 2017) |
| "Treatment with citalopram was associated with greater increase in tNO over 12 weeks compared to placebo (P = 0." | 2.74 | Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. ( Atar, D; Frasure-Smith, N; Laliberté, MA; Lespérance, F; Malinin, AI; Serebruany, VL; van Zyl, LT, 2009) |
| "Although depressive disorders have been associated with increased risk of worse outcomes with cardiovascular diseases (CVDs), its relation with access to and quality of cardiovascular care is not well studied." | 1.48 | Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease. ( Butler, J; Lacey, M; Parikh, PB; Shroyer, AL; Srivastava, P, 2018) |
| "Seventy seven patients with major depressive disorder (MDD), divided into two groups were included in the study." | 1.35 | Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. ( Bieńkiewicz, M; Gałecka, E; Gałecki, P; Szemraj, J; Zboralski, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Berk, M | 4 |
| Mohebbi, M | 2 |
| Dean, OM | 2 |
| Cotton, SM | 2 |
| Chanen, AM | 2 |
| Dodd, S | 3 |
| Ratheesh, A | 2 |
| Amminger, GP | 2 |
| Phelan, M | 2 |
| Weller, A | 1 |
| Mackinnon, A | 2 |
| Giorlando, F | 2 |
| Baird, S | 2 |
| Incerti, L | 1 |
| Brodie, RE | 1 |
| Ferguson, NO | 1 |
| Rice, S | 2 |
| Schäfer, MR | 2 |
| Mullen, E | 2 |
| Hetrick, S | 2 |
| Kerr, M | 2 |
| Harrigan, SM | 2 |
| Quinn, AL | 2 |
| Mazza, C | 2 |
| McGorry, P | 2 |
| Davey, CG | 2 |
| Woods, RL | 1 |
| Nelson, MR | 1 |
| Shah, RC | 1 |
| Reid, CM | 1 |
| Storey, E | 1 |
| Fitzgerald, S | 1 |
| Lockery, JE | 1 |
| Wolfe, R | 1 |
| Murray, AM | 1 |
| Stocks, N | 1 |
| Fitzgerald, PB | 1 |
| Agustini, B | 1 |
| McNeil, JJ | 1 |
| Zdanowicz, N | 1 |
| Reynaert, C | 1 |
| Jacques, D | 1 |
| Lepiece, B | 1 |
| Dubois, T | 1 |
| Srivastava, P | 1 |
| Butler, J | 1 |
| Shroyer, AL | 1 |
| Lacey, M | 1 |
| Parikh, PB | 1 |
| Dean, B | 1 |
| Gibbons, A | 1 |
| Gogos, A | 1 |
| Udawela, M | 1 |
| Thomas, E | 1 |
| Scarr, E | 1 |
| Ghanizadeh, A | 1 |
| Hedayati, A | 1 |
| Glaus, J | 1 |
| Vandeleur, CL | 1 |
| Lasserre, AM | 1 |
| Strippoli, MP | 1 |
| Castelao, E | 1 |
| Gholam-Rezaee, M | 1 |
| Waeber, G | 1 |
| Aubry, JM | 1 |
| Vollenweider, P | 1 |
| Preisig, M | 1 |
| Williams, A | 1 |
| O'Shea, M | 1 |
| Gałecki, P | 1 |
| Szemraj, J | 1 |
| Bieńkiewicz, M | 1 |
| Zboralski, K | 1 |
| Gałecka, E | 1 |
| Campos-Outcalt, D | 1 |
| Pasco, JA | 1 |
| Jacka, FN | 1 |
| Williams, LJ | 1 |
| Henry, MJ | 1 |
| Nicholson, GC | 1 |
| Kotowicz, MA | 1 |
| Andrade, C | 1 |
| Ernst, J | 1 |
| Mendlewicz, J | 1 |
| Kriwin, P | 1 |
| Oswald, P | 1 |
| Souery, D | 1 |
| Alboni, S | 1 |
| Brunello, N | 1 |
| van Zyl, LT | 1 |
| Lespérance, F | 1 |
| Frasure-Smith, N | 1 |
| Malinin, AI | 1 |
| Atar, D | 1 |
| Laliberté, MA | 1 |
| Serebruany, VL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aspirin in Reducing Events in the Elderly[NCT01038583] | 19,114 participants (Actual) | Observational | 2010-01-31 | Active, not recruiting | |||
| A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome[NCT05657860] | Phase 4 | 33 participants (Anticipated) | Interventional | 2020-12-17 | Recruiting | ||
| An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression[NCT05615948] | Phase 4 | 20 participants (Anticipated) | Interventional | 2022-12-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aspirin and Depressive Disorder, Major
| Article | Year |
|---|---|
Drug interactions in the treatment of depression in patients with ischemic heart disease.
Topics: Aged; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Comorbidity; Cytoc | 2012 |
Alternative treatment modalities in human immunodeficiency virus/acquired immune deficiency syndrome.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Complementary Therapies; | 2003 |
7 trials available for aspirin and Depressive Disorder, Major
| Article | Year |
|---|---|
Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Depre | 2020 |
Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial.
Topics: Aged; Aspirin; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Fe | 2020 |
Selective Serotonergic (SSRI) Versus Noradrenergic (SNRI) Reuptake Inhibitors with and without Acetylsalicylic Acid in Major Depressive Disorder.
Topics: Antidepressive Agents; Aspirin; Citalopram; Cyclooxygenase Inhibitors; Depressive Disorder, Major; D | 2017 |
Augmentation of citalopram with aspirin for treating major depressive disorder, a double blind randomized placebo controlled clinical trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antidepressive Agents, Second | 2014 |
Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Biomarkers; Depressi | 2018 |
Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents; Aspirin; Depressive Disorder, Major; Drug Re | 2006 |
Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents; Aspirin; Depressive Disorder, Major; Drug Re | 2006 |
Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents; Aspirin; Depressive Disorder, Major; Drug Re | 2006 |
Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents; Aspirin; Depressive Disorder, Major; Drug Re | 2006 |
Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study.
Topics: Adult; Aged; Antidepressive Agents; Aspirin; beta-Thromboglobulin; Biomarkers; Blood Platelets; Cita | 2009 |
6 other studies available for aspirin and Depressive Disorder, Major
| Article | Year |
|---|---|
Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease.
Topics: Age Distribution; Aged; Angina Pectoris; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2018 |
Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Bipolar Disorder; B | 2018 |
Aspirin and statin use and the subsequent development of depression in men and women: Results from a longitudinal population-based study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Depressive Disorder, | 2015 |
Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antioxidan | 2009 |
USPSTF recommendations you may have missed amid the breast cancer controversy.
Topics: Adolescent; Age Factors; Aspirin; Breast Neoplasms; Breast Self-Examination; Child; Depression; Depr | 2010 |
Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression.
Topics: Aspirin; Atorvastatin; Case-Control Studies; Confidence Intervals; Cytokines; Depressive Disorder, M | 2010 |